In line with these observations, a recent study from our group implicated SPRED1 deletions in the resistance to targeted therapies in BRAF-driven melanoma, demonstrating that loss of SPRED1 sustains the activity of WT RAS and reactivates the MAPK pathway in the context of BRAF-inhibition in vitro and in vivo (Ablain et al., 2021). The gene discussed is SPRED1; the disease is melanoma.